RxDoctor Payments Data

Angela Gaikowski, NP

Psychiatric/Mental Health · Aberdeen, SDNPI 1275788960

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations.

$722in general payments, 2019–2025

Across 47 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$108
  • Lilly USA, LLC$106
  • AbbVie$82
  • Novartis$66
  • Johnson & Johnson$60
  • Pharmacosmos Therapeutics Inc.$36
  • plus $264 from 10 others

What the payments were for

  • Food & beverage$722100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$722 in reported general payments places this provider in the 55th percentile of 77 psychiatric/mental health providers in South Dakota.

See all psychiatric/mental health providers in South Dakota

Medicare billing

Part B allowed, 2024
$1,654
Medicare patients
11
Services billed
21

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin49$66,973
EliquisApixaban47$58,606
MounjaroTirzepatide49$49,194
XareltoRivaroxaban28$33,077
OzempicSemaglutide25$29,753
TrulicityDulaglutide17$17,560
LinzessLinaclotide13$16,988
Janumet XrSitagliptin Phos/Metformin Hcl11$16,553
Tresiba Flextouch U-100Insulin Degludec19$13,990
AbrysvoRsv Vacc, Pref A And Pref B/Pf46$13,861
Fiasp FlextouchInsulin Aspart (Niacinamide)18$13,214
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,982
Combivent RespimatIpratropium/Albuterol Sulfate13$6,216
Novolog FlexpenInsulin Aspart21$4,322
Duloxetine Hcl103$4,285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$29$72,46793 claims
Lilly USA, LLCMounjaro, Trulicity$106$66,75466 claims
Johnson & JohnsonXarelto$60$33,07728 claims
Novo NordiskOzempic$28$29,75325 claims
AbbVieLinzess, Synthroid$82$17,88736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 77 psychiatric/mental health providers in South Dakota.

Other psychiatric/mental health in Aberdeen

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →